

# FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response...	0.5

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person* Furlow Brenda S.			2. Issuer Name and Ticker or Trading Symbol BIO-TECHNE Corp [TECH]			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director _____ 10% Owner _____ <input checked="" type="checkbox"/> Officer (give title below) _____ Other (specify below) _____ SVP - General Counsel		
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 12/12/2019					
614 MCKINLEY PLACE NE								
(Street)			4. If Amendment, Date Original Filed(Month/Day/Year)			6. Individual or Joint/Group Filing(Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person		
MINNEAPOLIS, MN 55413								
(City)			(State)			(Zip)		

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
			Code	V	Amount	(A) or (D)	Price				
Common Stock	11/12/2019		G	V	492	(1)	D	\$ 0	2,711	D	
Common Stock	12/12/2019		M		8,000		A	\$ 94.35	10,711	D	
Common Stock	12/12/2019		S	(2)	426		D	\$ 214.3196 (3)	10,285	D	
Common Stock	12/12/2019		S	(2)	3,227		D	\$ 215.1651 (4)	7,058	D	
Common Stock	12/12/2019		S	(2)	4,147		D	\$ 216.0077 (5)	2,911	D	
Common Stock	12/12/2019		S	(2)	200		D	\$ 216.75 (6)	2,711	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.** SEC 1474 (9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V		Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Options (Right to Buy)	\$ 94.35	12/12/2019		M		8,000	(8)	08/12/2021	Common Stock	8,000	\$ 0	1,600	D	
Stock Options (Right to Buy)	\$ 108.49						(8)	08/07/2022	Common Stock	10,000		10,000	D	
Stock Options (Right to Buy)	\$ 108.49						(8)	08/07/2022	Common Stock	5,995		5,995	D	

Stock Options (Right to Buy)	\$ 106.59							(8)	08/18/2023	Common Stock	10,857		10,857	D
Stock Options (Right to Buy)	\$ 106.59							(12)	08/18/2023	Common Stock	14,476		14,476	D
Restricted Stock Units	(7)							(15)	(15)	Common Stock	1,724		1,724	D
Stock Options (Right to Buy)	\$ 125.05							(15)	08/09/2024	Common Stock	9,503		9,503	D
Stock Options (Right to Buy)	\$ 125.05							(10)	08/09/2024	Common Stock	12,670		12,670	D
Restricted Stock Units	(7)							(14)	(14)	Common Stock	1,374		1,374	D
Stock Options (Right to Buy)	\$ 177.32							(14)	08/08/2025	Common Stock	7,339		7,339	D
Stock Options (Right to Buy)	\$ 177.32							(9)	08/08/2025	Common Stock	9,786		9,786	D
Restricted Stock Units	(7)							(13)	(13)	Common Stock	1,969		1,969	D
Stock Options (Right to Buy)	\$ 190.41							(13)	08/07/2026	Common Stock	9,968		9,968	D
Stock Options (Right to Buy)	\$ 190.41							(11)	08/07/2026	Common Stock	13,290		13,290	D

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Furlow Brenda S. 614 MCKINLEY PLACE NE MINNEAPOLIS, MN 55413			SVP - General Counsel	

## Signatures

/s/ Andrew Nick as Attorney-in-Fact for Brenda S. Furlow pursuant to Power of Attorney previously filed.		12/17/2019
<small>**Signature of Reporting Person</small>		<small>Date</small>

## Explanation of Responses:

\* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Represents a transfer of shares to a charitable donor advised fund. The reporting person retained no pecuniary interest in the transferred shares.

(2) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2019.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$213.67 to \$214.66 inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

(3)

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$214.69 to \$215.68 inclusive. The reporting person  
(4) undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$215.69 to \$216.53 inclusive. The reporting person  
(5) undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$216.71 to \$216.79 inclusive. The reporting person  
(6) undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

(7) Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.

(8) Fully exercisable.

(9) Options to purchase 2,447 shares vest on each of 8/8/2019 and 8/8/2020 and options to purchase 2,446 shares vest on each of 8/8/2021 and 8/8/2022.

(10) Options to purchase 3,167 shares vest on each of 8/9/2018 and 8/9/2019 and options to purchase 3,168 shares vest on each of 8/9/2020 and 8/9/2021.

(11) Options to purchase 3,323 shares vest on each of 8/7/2020 and 8/7/2021 and options to purchase 3,322 shares vest on each of 8/7/2022 and 8/7/2023.

(12) Options to purchase 3,619 shares vest on each of 8/18/2017, 8/18/2018, 8/18/2019 and 8/18/2020.

(13) Vests in full or in part on 8/7/2022 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

(14) Vests in full or in part on 8/8/2021 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

(15) Vests in full or in part on 8/9/2020 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.